HeartSciences Inc. (HSCS)

NASDAQ: HSCS · Real-Time Price · USD
3.330
-0.220 (-6.20%)
At close: Jul 30, 2025, 4:00 PM
3.270
-0.060 (-1.80%)
After-hours: Jul 30, 2025, 6:22 PM EDT
-6.20%
Market Cap6.44M
Revenue (ttm)4,350
Net Income (ttm)-8.77M
Shares Out 1.93M
EPS (ttm)-9.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume112,384
Open3.550
Previous Close3.550
Day's Range3.040 - 3.625
52-Week Range2.360 - 6.470
Beta2.59
AnalystsStrong Buy
Price Target13.00 (+290.39%)
Earnings DateJul 24, 2025

About HSCS

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction as well as conventional ECG information in the same test; and Myo... [Read more]

Sector Healthcare
IPO Date Jun 15, 2022
Employees 15
Stock Exchange NASDAQ
Ticker Symbol HSCS
Full Company Profile

Financial Performance

In 2025, HeartSciences's revenue was $4,350, a decrease of -76.61% compared to the previous year's $18,600. Losses were -$8.77 million, 32.7% more than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for HSCS stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 290.39% from the latest price.

Price Target
$13.0
(290.39% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company trans...

6 days ago - GlobeNewsWire

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Southlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focus...

2 months ago - GlobeNewsWire

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

Southlake, TX, June 03, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focus...

2 months ago - GlobeNewsWire

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company focuse...

2 months ago - GlobeNewsWire

HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc . (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on tran...

2 months ago - GlobeNewsWire

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on trans...

2 months ago - GlobeNewsWire

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on tran...

3 months ago - GlobeNewsWire

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

Southlake, TX, May 01, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focuse...

3 months ago - GlobeNewsWire

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focu...

4 months ago - GlobeNewsWire

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focu...

5 months ago - GlobeNewsWire

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused...

8 months ago - GlobeNewsWire

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered med...

9 months ago - GlobeNewsWire

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered me...

10 months ago - GlobeNewsWire

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered me...

11 months ago - GlobeNewsWire

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered me...

11 months ago - GlobeNewsWire

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered med...

1 year ago - GlobeNewsWire

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered med...

1 year ago - GlobeNewsWire

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

Southlake, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered med...

1 year ago - GlobeNewsWire

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Southlake, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered ...

1 year ago - GlobeNewsWire

HeartSciences Regains Compliance with Nasdaq Listing Requirements

Southlake, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered med...

1 year ago - GlobeNewsWire

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered m...

1 year ago - GlobeNewsWire

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease Patent covers use of AI-ECG for any echo measure of di...

1 year ago - GlobeNewsWire

HeartSciences to Present at the LD Micro Invitational XIV Conference

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences  (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered m...

1 year ago - GlobeNewsWire

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LV...

1 year ago - GlobeNewsWire

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered me...

1 year ago - GlobeNewsWire